TearLab Corporation (NASDAQ:TEAR) Given Consensus Rating of “Buy” by Analysts
Shares of TearLab Corporation (NASDAQ:TEAR) have earned an average rating of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $5.75.
Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $4.00 target price on shares of TearLab Corporation in a report on Tuesday, May 16th. Rodman & Renshaw reduced their target price on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, May 16th. Finally, Zacks Investment Research lowered shares of TearLab Corporation from a “buy” rating to a “hold” rating in a report on Tuesday, May 16th.
Shares of TearLab Corporation (TEAR) remained flat at $1.70 during trading on Monday. The company’s stock had a trading volume of 121,720 shares. The firm has a 50 day moving average of $1.90 and a 200 day moving average of $3.62. The stock’s market capitalization is $9.75 million. TearLab Corporation has a one year low of $1.55 and a one year high of $9.00.
TearLab Corporation (NASDAQ:TEAR) last released its earnings results on Monday, May 15th. The medical research company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.07. The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $7.02 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. The business’s revenue was down 1.5% compared to the same quarter last year. On average, equities research analysts forecast that TearLab Corporation will post ($2.82) EPS for the current year.
TearLab Corporation Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.